sarcoidosis%20-%20pulmonary
SARCOIDOSIS - PULMONARY
Sarcoidosis is a multisystem disease which may present with non-specific symptoms or symptoms related to organ-specific involvement.
Non-specific symptoms include fever, malaise, fatigue and weight loss.
Pulmonary involvement is seen in >90% of sarcoidosis patients.

Follow Up

General Surveillance Principles

  • Sarcoidosis patients should be monitored regularly
  • Monitoring should include a review of symptoms, physical exam, CXR & lung function tests
    • Perform other tests as necessary based on organ involvement
  • Monitor & treat patients for complications of sarcoidosis & related conditions (eg aspergilloma, osteoporosis, hypercalcemia, hypercalciuria)
  • Patients who have undergone therapy should be monitored for 3 years after cessation of treatment
  • Intermittent monitoring (every 3-6 months) is recommended for patients on TNF-alpha inhibitor therapy

Monitoring Intervals Based on Disease Stage

Stage 1

  • Initially every 6 months then once a year if stable

Stage 2, 3, 4

  • Initially every 3-6 months; monitor indefinitely

Serious extrapulmonary involvement, regardless of radiographic stage

  • Monitor indefinitely
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
16 Jan 2017
There are various ear, nose, and throat (ENT) conditions which present to the GP’s clinic. Dr Jason Hwang, an ENT Consultant from the Department of Otolaryngology at Gleneagles Hospital in Singapore, speaks on how the majority of the conditions can be effectively managed at the primary care level seeing that these can be treated medically without the need for surgical intervention.
16 Dec 2016
Two of the most common hospital-acquired, ventilator-associated nonfermentative gram-negative pneumonia pathogens—Acinetobacter baumannii and Pseudomonas aeruginosa—develop significant resistance to most therapeutic options available, and they should be managed with combination therapies until new antimicrobial agents are developed, according to a study.
24 May 2018
In children and adolescents with cystic fibrosis (CF), synbiotic supplementation appears to be effective at reducing proinflammatory markers such as interleukin (IL)-6 and -8, and nitric oxide metabolites (NOx), a recent study has found.
15 Apr 2018
The use of transbronchial lung biopsy (TBLB) appears to be safe and effective for the pathological diagnosis of lymphangioleiomyomatosis (LAM), suggests a recent study.